Friday, 20 November 2026European Markets

MEDINCELL Stock 11.56% Up Before The Weekend

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - the market ended the session with medincell (medcl.pa) jumping 11.56% to €7.14 on friday while cac 40 jumped 0.75% to €7,315.07.

medincell's last close was €6.40, 39.05% below its 52-week high of €10.50.

about medincell

medincell s.a. develops various therapeutic solutions in france. it develops solutions based on bepo, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. the company's products in development include mdc-irm, a risperidone extended-release injectable suspension completed phase iii trial for use in the treatment of schizophrenia; mdc-cwm, a sustained-release formulation of celecoxib in phase iii trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-tjk, a subcutaneous injection in phase iii trials for use in the treatment of schizophrenia. its product candidates in preclinical trials, such as mdc-ang, an antipsychotic product for use in the treatment of schizophrenia; mdc-ttg for covid-19 and its variants; mdc-grt for use in organ transplant; mdc-wwm for contraception; mdc-stm for use in malaria; mdc-kpt for use in acute pain for pets; and mdc-irm for use in neuroscience. the company was incorporated in 2003 and is based in jacou, france.

earnings per share

as for profitability, medincell has a trailing twelve months eps of €-1.06.

volatility

medincell's last week, last month's, and last quarter's current intraday variation average was 0.40%, 0.12%, and 2.22%.

medincell's highest amplitude of average volatility was 0.95% (last week), 1.22% (last month), and 2.22% (last quarter).

yearly top and bottom value

medincell's stock is valued at €7.14 at 22:31 est, way below its 52-week high of €10.50 and way above its 52-week low of €4.73.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, medincell's stock is considered to be oversold (<=20).

revenue growth

year-on-year quarterly revenue growth grew by 77140%, now sitting on 9.89m for the twelve trailing months.

more news about medincell (medcl.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 4 Aug 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›